{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:48:23Z","timestamp":1790894903738,"version":"4.1.0"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.pnpbp.2018.07.017","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T16:36:12Z","timestamp":1532536572000},"page":"290-297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"PB","title":["Overlaps in pharmacology for the treatment of chronic pain and mental health disorders"],"prefix":"10.1016","volume":"87","author":[{"given":"Ainsley M.","family":"Sutherland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hance","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.pnpbp.2018.07.017_bb0005","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1212\/01.wnl.0000253187.66183.9c","article-title":"Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial","volume":"68","author":"Abrams","year":"2007","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.pnpbp.2018.07.017_bb0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2165\/11533440-000000000-00000","volume":"30","author":"Afilalo","year":"2010","journal-title":"Clinical Drug Investig."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0015","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/JPR.S55682","article-title":"Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy","volume":"7","author":"Allen","year":"2014","journal-title":"J. Pain Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.07.017_bb0020","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/cpdd.271","article-title":"Clinical experience with desvenlafaxine in treatment of patients with fibromyalgia syndrome","volume":"6","author":"Allen","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0025","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0306-4522(96)00063-2","article-title":"Direct evidence of an extensive GABAergic innervation of the spinal dorsal horn by fibres descending from the rostral ventromedial medulla","volume":"73","author":"Antal","year":"1996","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0030","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/art.22457","article-title":"Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"56","author":"Arnold","year":"2007","journal-title":"Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.pnpbp.2018.07.017_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/j.1468-1331.2010.02999.x","article-title":"EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision","volume":"17","author":"Attal","year":"2010","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0040","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/24740527.2017.1325317","article-title":"Acceptance and commitment therapy to manage pain and opioid use after major surgery: preliminary outcomes from the Toronto General Hospital Transitional Pain Service","volume":"1","author":"Azam","year":"2017","journal-title":"Can. J. Pain"},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0045","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cne.901780203","article-title":"Three bulbospinal pathways from the rostral medulla of the cat: an autoradiographic study of pain modulating systems","volume":"178","author":"Basbaum","year":"1978","journal-title":"J. Comp. Neurol."},{"issue":"13","key":"10.1016\/j.pnpbp.2018.07.017_bb0055","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1523\/JNEUROSCI.0356-09.2009","article-title":"The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin","volume":"29","author":"Bauer","year":"2009","journal-title":"J. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.07.017_bb0060","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.drugalcdep.2007.09.018","article-title":"Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates","volume":"94","author":"Becker","year":"2008","journal-title":"Drug Alcohol Depend."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.07.017_bb0065","article-title":"Gabapentin therapy in psychiatric disorders: a systematic review","volume":"17","author":"Berlin","year":"2015","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"9164","key":"10.1016\/j.pnpbp.2018.07.017_bb0070","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0140-6736(99)01313-6","article-title":"The neurobiology of pain","volume":"353","author":"Besson","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S1461145712000119","article-title":"The evidence-based pharmacotherapy of social anxiety disorder","volume":"16","author":"Blanco","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0080","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jamapsychiatry.2015.3229","article-title":"Cannabis use and risk of psychiatric disorders: prospective evidence from a US National Longitudinal Study","volume":"73","author":"Blanco","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2018.07.017_bb0085","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ejpain.2009.11.014","article-title":"Mu-opioid receptors are not necessary for nortriptyline treatment of neuropathic allodynia","volume":"14","author":"Bohren","year":"2010","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.nbd.2013.08.012","article-title":"Antidepressants suppress neuropathic pain by a peripheral beta2-adrenoceptor mediated anti-TNFalpha mechanism","volume":"60","author":"Bohren","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0095","doi-asserted-by":"crossref","first-page":"7","DOI":"10.11607\/ofph.1274","article-title":"The effectiveness of cannabinoids in the management of chronic nonmalignant neuropathic pain: a systematic review","volume":"29","author":"Boychuk","year":"2015","journal-title":"J. Oral Facial Pain Headache"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0100","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1213\/01.ANE.0000152191.29311.9B","article-title":"Age-dependent opioid escalation in chronic pain patients","volume":"100","author":"Buntin-Mushock","year":"2005","journal-title":"Anesth. Analg."},{"issue":"9169","key":"10.1016\/j.pnpbp.2018.07.017_bb0105","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(99)03313-9","article-title":"Acute pain","volume":"353","author":"Carr","year":"1999","journal-title":"Lancet"},{"issue":"Pt B","key":"10.1016\/j.pnpbp.2018.07.017_bb0110","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuropharm.2013.08.028","article-title":"15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse","volume":"76","author":"Charbogne","year":"2014","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.07.017_bb0115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1254\/jphs.CR0050020","article-title":"Mechanisms of the Antinociceptive action of gabapentin","volume":"100","author":"Cheng","year":"2006","journal-title":"J. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0120","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1471-4159.2005.03263.x","article-title":"Evidence that gabapentin reduces neuropathic pain by inhibiting the spinal release of glutamate","volume":"94","author":"Coderre","year":"2005","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0125","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5498\/wjp.v5.i4.366","article-title":"Treating comorbid anxiety and depression: psychosocial and pharmacological approaches","volume":"5","author":"Coplan","year":"2015","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jpsychires.2015.05.004","article-title":"Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC)","volume":"66\u201367","author":"Cougle","year":"2015","journal-title":"J. Psychiatr. Res."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0135","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/BF02244985","article-title":"Binding of antidepressants to human brain receptors: focus on newer generation compounds","volume":"114","author":"Cusack","year":"1994","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12325-013-0088-2","article-title":"Pharmacoeconomic outcomes for pregabalin: a systematic review in neuropathic pain, generalized anxiety disorder, and epilepsy from a Spanish perspective","volume":"31","author":"Darba","year":"2014","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beem.2008.10.013","article-title":"An introduction to the endocannabinoid system: from the early to the latest concepts","volume":"23","author":"De Petrocellis","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011605","article-title":"Nortriptyline for neuropathic pain in adults","volume":"1","author":"Derry","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0155","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0304-3959(79)90122-2","article-title":"Inhibition of the spinal transmission of nociceptive information by supraspinal stimulation in the cat","volume":"6","author":"Duggan","year":"1979","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.pnpbp.2018.07.017_bb0160","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.07.017_bb0165","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/00000542-199511000-00018","article-title":"Intrathecal amitriptyline acts as an N-methyl-D-aspartate receptor antagonist in the presence of inflammatory hyperalgesia in rats","volume":"83","author":"Eisenach","year":"1995","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.pnpbp.2018.07.017_bb0170","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/npp.2008.120","article-title":"Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial","volume":"34","author":"Ellis","year":"2009","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.07.017_bb0175","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.lfs.2005.09.011","article-title":"Chemical constituents of marijuana: the complex mixture of natural cannabinoids","volume":"78","author":"Elsohly","year":"2005","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0180","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.cell.2009.09.025","article-title":"Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis","volume":"139","author":"Eroglu","year":"2009","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0185","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/j.1360-0443.2008.02221.x","article-title":"Cannabis use and later life outcomes","volume":"103","author":"Fergusson","year":"2008","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.pnpbp.2018.07.017_bb0190","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1021\/jm060650z","article-title":"Ca2+ channel alpha2-delta ligands for the treatment of neuropathic pain","volume":"50","author":"Field","year":"2007","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0195","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.pmr.2015.01.002","article-title":"Sleep: important considerations in management of pain","volume":"26","author":"Fine","year":"2015","journal-title":"Phys. Med. Rehabil. Clin. N. Am."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0200","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","article-title":"Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis","volume":"14","author":"Finnerup","year":"2015","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.pnpbp.2018.07.017_bb0205","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jpain.2012.07.013","article-title":"The prevalence of mental health and pain symptoms in general population samples reporting nonmedical use of prescription opioids: a systematic review and meta-analysis","volume":"13","author":"Fischer","year":"2012","journal-title":"J. Pain"},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0210","article-title":"Venlafaxine for neuropathic pain in adults","volume":"8","author":"Gallagher","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0215","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bjp.0707253","article-title":"Tricyclic antidepressant pharmacology and therapeutic drug interactions updated","volume":"151","author":"Gillman","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.pnpbp.2018.07.017_bb0220","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1097\/FPC.0000000000000057","article-title":"PharmGKB summary: tramadol pathway","volume":"24","author":"Gong","year":"2014","journal-title":"Pharmacogenet. Genomics"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0225","first-page":"214","article-title":"Benzodiazepine pharmacology and central nervous system\u2013mediated effects","volume":"13","author":"Griffin","year":"2013","journal-title":"Ochsner J."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0306-4522(01)00287-1","article-title":"Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus","volume":"106","author":"Hajos","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0235","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011003","article-title":"Imipramine for neuropathic pain in adults","volume":"5","author":"Hearn","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"7","key":"10.1016\/j.pnpbp.2018.07.017_bb0240","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.mayocp.2016.04.029","article-title":"Chronic pain and mental health disorders: shared neural mechanisms, epidemiology, and treatment","volume":"91","author":"Hooten","year":"2016","journal-title":"Mayo Clin. Proc."},{"issue":"10","key":"10.1016\/j.pnpbp.2018.07.017_bb0245","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.tips.2009.07.006","article-title":"Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb","volume":"30","author":"Izzo","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0250","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1532-5415.2012.03923.x","volume":"60","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/0897190013515001","article-title":"Benzodiazepines: a major component in unintentional prescription drug overdoses with opioid analgesics","volume":"27","author":"Jann","year":"2014","journal-title":"J. Pharm. Pract."},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2018.07.017_bb0260","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drugalcdep.2012.07.004","article-title":"Polydrug abuse: a review of opioid and benzodiazepine combination use","volume":"125","author":"Jones","year":"2012","journal-title":"Drug Alcohol Depend."},{"issue":"2S","key":"10.1016\/j.pnpbp.2018.07.017_bb0265","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.36076\/ppj.2017.s111","article-title":"Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse: part 1","volume":"20","author":"Kaye","year":"2017","journal-title":"Pain Phys."},{"issue":"2S","key":"10.1016\/j.pnpbp.2018.07.017_bb0270","first-page":"S111","article-title":"Prescription opioid abuse in chronic pain: an updated review of opioid abuse predictors and strategies to curb opioid abuse (part 2)","volume":"20","author":"Kaye","year":"2017","journal-title":"Pain Phys."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.07.017_bb0275","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1176\/appi.psy.46.5.379","article-title":"Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain","volume":"46","author":"Krell","year":"2005","journal-title":"Psychosomatics"},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0280","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuroscience.2016.06.057","article-title":"Antidepressants and gabapentinoids in neuropathic pain: mechanistic insights","volume":"338","author":"Kremer","year":"2016","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0285","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3233\/NRE-2010-0596","article-title":"Spasticity: revisiting the role and the individual value of several pharmacological treatments","volume":"27","author":"Lapeyre","year":"2010","journal-title":"NeuroRehabilitation"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0290","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3346\/jkms.2013.28.2.308","article-title":"Intrathecal gabapentin increases interleukin-10 expression and inhibits pro-inflammatory cytokine in a rat model of neuropathic pain","volume":"28","author":"Lee","year":"2013","journal-title":"J. Korean Med. Sci."},{"issue":"8","key":"10.1016\/j.pnpbp.2018.07.017_bb0295","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/1060028015585849","article-title":"The role of gabapentin in the management of alcohol withdrawal and dependence","volume":"49","author":"Leung","year":"2015","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0300","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1523\/JNEUROSCI.13-06-02273.1993","article-title":"Peptides and the primary afferent nociceptor","volume":"13","author":"Levine","year":"1993","journal-title":"J. Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2018.07.017_bb0305","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2011.05.054","article-title":"Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits","volume":"667","author":"Li","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.pnpbp.2018.07.017_bb0310","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jpain.2009.10.012","article-title":"Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain","volume":"11","author":"Liebschutz","year":"2010","journal-title":"J. Pain"},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0315","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia","volume":"1","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0320","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1523\/JNEUROSCI.21-06-01868.2001","article-title":"Upregulation of dorsal root ganglion (alpha)2(delta) calcium channel subunit and its correlation with allodynia in spinal nerve-injured rats","volume":"21","author":"Luo","year":"2001","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.07.017_bb0325","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1124\/jpet.102.041574","article-title":"Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin","volume":"303","author":"Luo","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0330","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpainsymman.2013.02.018","article-title":"A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain","volume":"47","author":"Lynch","year":"2014","journal-title":"J. Pain Symptom Manag."},{"issue":"3","key":"10.1016\/j.pnpbp.2018.07.017_bb0335","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0304-3959(03)00168-4","article-title":"Evidence for a monoamine mediated, opioid-independent, antihyperalgesic effect of venlafaxine, a non-tricyclic antidepressant, in a neurogenic pain model in rats","volume":"103","author":"Marchand","year":"2003","journal-title":"Pain"},{"issue":"7","key":"10.1016\/j.pnpbp.2018.07.017_bb0340","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrn1700","article-title":"Role of the immune system in chronic pain","volume":"6","author":"Marchand","year":"2005","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0345","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neulet.2013.11.017","article-title":"Presynaptic inhibitory actions of pregabalin on excitatory transmission in superficial dorsal horn of mouse spinal cord: further characterization of presynaptic mechanisms","volume":"558","author":"Matsuzawa","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0350","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1146\/annurev.physiol.61.1.835","article-title":"Ion channels of nociception","volume":"61","author":"McCleskey","year":"1999","journal-title":"Annu. Rev. Physiol."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0355","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/bjaceaccp\/mki004","article-title":"Opioid receptors","volume":"5","author":"McDonald","year":"2005","journal-title":"Contin. Educ. Anaesth. Crit. Care Pain"},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2018.07.017_bb0360","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3959(03)00301-4","article-title":"Mood and anxiety disorders associated with chronic pain: an examination in a nationally representative sample","volume":"106","author":"McWilliams","year":"2003","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0365","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1111\/bph.12963","article-title":"Kappa-opioid receptors are not necessary for the antidepressant treatment of neuropathic pain","volume":"172","author":"Megat","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.07.017_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153380","article-title":"Comparative safety of pharmacologic treatments for persistent depressive disorder: a systematic review and network meta-analysis","volume":"11","author":"Meister","year":"2016","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.pnpbp.2018.07.017_bb0375","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.tips.2006.05.004","article-title":"Antidepressants and pain","volume":"27","author":"Mico","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0380","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007938","article-title":"Pregabalin for acute and chronic pain in adults","volume":"3","author":"Moore","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0385","article-title":"Gabapentin for chronic neuropathic pain and fibromyalgia in adults","volume":"4","author":"Moore","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011603","article-title":"Amitriptyline for neuropathic pain in adults","volume":"7","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0395","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1097\/j.pain.0000000000000892","article-title":"Polysubstance use and misuse or abuse of prescription opioid analgesics: a multi-level analysis of international data","volume":"158","author":"Morley","year":"2017","journal-title":"Pain"},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0400","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1155\/2014\/754693","article-title":"Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society","volume":"19","author":"Moulin","year":"2014","journal-title":"Pain Res. Manag."},{"issue":"5","key":"10.1016\/j.pnpbp.2018.07.017_bb0405","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.pain.2012.01.029","article-title":"An increase in spinal cord noradrenaline is a major contributor to the antihyperalgesic effect of antidepressants after peripheral nerve injury in the rat","volume":"153","author":"Nakajima","year":"2012","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0410","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/pme.12594","article-title":"Benzodiazepine use among chronic pain patients prescribed opioids: associations with pain, physical and mental health, and health service utilization","volume":"16","author":"Nielsen","year":"2015","journal-title":"Pain Med."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0415","article-title":"Long-term opioid management for chronic noncancer pain","volume":"1","author":"Noble","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"20","key":"10.1016\/j.pnpbp.2018.07.017_bb0420","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.2174\/1381612043383872","article-title":"Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?","volume":"10","author":"Pacher","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0425","first-page":"503","article-title":"Preliminary note on the action of imipramine in painful states","volume":"102","author":"Paoli","year":"1960","journal-title":"Rev. Neurol. (Paris)"},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0430","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2698","article-title":"Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study","volume":"350","author":"Park","year":"2015","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0435","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.205","article-title":"Mechanisms of the gabapentinoids and alpha 2 delta-1 calcium channel subunit in neuropathic pain","volume":"4","author":"Patel","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0440","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/01.yic.0000224782.83287.3c","article-title":"Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?","volume":"21","author":"Perahia","year":"2006","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0445","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/bja\/71.1.119","article-title":"Opioid receptors and their relevance to anaesthesia","volume":"71","author":"Pleuvry","year":"1993","journal-title":"Br. J. Anaesth."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0450","first-page":"40","article-title":"Antimuscarinic and other receptor-blocking properties of antidepressants","volume":"58","author":"Richelson","year":"1983","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0455","article-title":"Antidepressants for neuropathic pain","volume":"4","author":"Saarto","year":"2007","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0460","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/ALN.0000000000000902","article-title":"Efficacy of duloxetine in chronic low back pain with a neuropathic component: a randomized, double-blind, placebo-controlled Crossover Trial","volume":"124","author":"Schukro","year":"2016","journal-title":"Anesthesiology"},{"issue":"3","key":"10.1016\/j.pnpbp.2018.07.017_bb0465","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.pharmthera.2011.06.005","article-title":"Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors","volume":"132","author":"Serrano","year":"2011","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0470","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00000542-199101000-00010","article-title":"Pharmacokinetics, pharmacodynamics, and rational opioid selection","volume":"74","author":"Shafer","year":"1991","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0475","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0026-895X(25)00612-1","article-title":"Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate","volume":"36","author":"Sills","year":"1989","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0480","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1742-7843.2005.pto_96696601.x","article-title":"Antidepressants in the treatment of neuropathic pain","volume":"96","author":"Sindrup","year":"2005","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"12","key":"10.1016\/j.pnpbp.2018.07.017_bb0485","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jpain.2010.03.002","article-title":"Duloxetine versus placebo in patients with chronic low back pain: a 12-week, fixed-dose, randomized, double-blind trial","volume":"11","author":"Skljarevski","year":"2010","journal-title":"J. Pain"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.07.017_bb0490","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1526-4637.2010.00836.x","article-title":"Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study","volume":"11","author":"Skljarevski","year":"2010","journal-title":"Pain Med."},{"issue":"13","key":"10.1016\/j.pnpbp.2018.07.017_bb0495","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.pnpbp.2018.07.017_bb0500","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00019052-200310000-00009","article-title":"Painful neuropathies","volume":"16","author":"Sommer","year":"2003","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0505","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bbr.2017.02.041","article-title":"Panicolytic-like effect of tramadol is mediated by opioid receptors in the dorsal periaqueductal grey","volume":"326","author":"de Souza Fiaes","year":"2017","journal-title":"Behav. Brain Res."},{"issue":"25","key":"10.1016\/j.pnpbp.2018.07.017_bb0510","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199506223322506","article-title":"The control of pain in peripheral tissue by opioids","volume":"332","author":"Stein","year":"1995","journal-title":"N. Engl. J. Med."},{"issue":"2\u20133","key":"10.1016\/j.pnpbp.2018.07.017_bb0515","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ejphar.2008.04.043","article-title":"Antinociception occurs with a reversal in alpha 2-adrenoceptor regulation of TNF production by peripheral monocytes\/macrophages from pro- to anti-inflammatory","volume":"588","author":"Sud","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0520","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1360-0443.2007.02056.x","article-title":"Gender and non-medical use of prescription opioids: results from a national US survey","volume":"103","author":"Tetrault","year":"2008","journal-title":"Addiction"},{"issue":"2 Suppl","key":"10.1016\/j.pnpbp.2018.07.017_bb0525","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.36076\/ppj.2008\/11\/S133","article-title":"Opioid pharmacology","volume":"11","author":"Trescot","year":"2008","journal-title":"Pain Phys."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0530","article-title":"Muscle relaxants for non-specific low back pain","volume":"2","author":"van Tulder","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"issue":"23","key":"10.1016\/j.pnpbp.2018.07.017_bb0535","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0540","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/01.j.pain.0000460357.01998.f1","article-title":"Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis","volume":"156","author":"Vowles","year":"2015","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0545","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.pain.2010.09.005","article-title":"Duloxetine in patients with central neuropathic pain caused by spinal cord injury or stroke: a randomized, double-blind, placebo-controlled trial","volume":"152","author":"Vranken","year":"2011","journal-title":"Pain"},{"issue":"7","key":"10.1016\/j.pnpbp.2018.07.017_bb0550","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jpain.2015.03.008","article-title":"Efficacy of inhaled Cannabis on painful diabetic neuropathy","volume":"16","author":"Wallace","year":"2015","journal-title":"J. Pain"},{"issue":"7","key":"10.1016\/j.pnpbp.2018.07.017_bb0555","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/pme.12800","article-title":"Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta-analysis of randomized controlled trials","volume":"16","author":"Wang","year":"2015","journal-title":"Pain Med."},{"issue":"14","key":"10.1016\/j.pnpbp.2018.07.017_bb0560","doi-asserted-by":"crossref","first-page":"E694","DOI":"10.1503\/cmaj.091414","article-title":"Smoked cannabis for chronic neuropathic pain: a randomized controlled trial","volume":"182","author":"Ware","year":"2010","journal-title":"CMAJ"},{"issue":"4","key":"10.1016\/j.pnpbp.2018.07.017_bb0565","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/AJP.0b013e3180330dc5","article-title":"Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain","volume":"23","author":"Wasan","year":"2007","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0570","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2147\/JPR.S124566","article-title":"A case report on the treatment of complex chronic pain and opioid dependence by a multidisciplinary transitional pain service using the ACT matrix and buprenorphine\/naloxone","volume":"10","author":"Weinrib","year":"2017","journal-title":"J. Pain Res."},{"key":"10.1016\/j.pnpbp.2018.07.017_bb0575","article-title":"Gabapentin for chronic neuropathic pain in adults","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.pnpbp.2018.07.017_bb0580","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jpain.2007.12.010","article-title":"A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain","volume":"9","author":"Wilsey","year":"2008","journal-title":"J. Pain"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0585","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","article-title":"Low-dose vaporized cannabis significantly improves neuropathic pain","volume":"14","author":"Wilsey","year":"2013","journal-title":"J. Pain"},{"issue":"2","key":"10.1016\/j.pnpbp.2018.07.017_bb0590","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.neuroscience.2006.09.044","article-title":"Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit","volume":"144","author":"Xiao","year":"2007","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pnpbp.2018.07.017_bb0595","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.neulet.2007.12.037","article-title":"Repeated administration of mirtazapine inhibits development of hyperalgesia\/allodynia and activation of NF-kappaB in a rat model of neuropathic pain","volume":"433","author":"Zhu","year":"2008","journal-title":"Neurosci. Lett."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617303822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584617303822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T01:22:09Z","timestamp":1751764929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584617303822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":119,"alternative-id":["S0278584617303822"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.07.017","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overlaps in pharmacology for the treatment of chronic pain and mental health disorders","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2018.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}